Latin America’s largest medical diagnostic company taps into SOPHiA’s new multimodal solution to fight cancer, fostering a new Data-Driven Medicine era

São Paulo, Brazil, July 23, 2020: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today the signature of a Trial Match agreement with Dasa, the largest medical diagnostic company in Latin America. The group chose the SOPHiA Platform to lead the region toward an extensive approach to Data-Driven Medicine powered by the world’s first integrated multimodal solution to fight cancer.